I’ve raised capital. I’ve deployed capital. I’ve walked into boardrooms as the operator who has to deliver on the promises made in a pitch deck. I’ve also sat on the investor side, on fund committees and in deal meetings, evaluating the same kinds of companies I’ve built. Over the past decade, as more generalist investors have entered women’s health, I’ve watched the same patterns play out from both sides of the table.
The capital is arriving. But most of it is arriving with the wrong assumptions.
Here’s what the market looks like from inside, and what it costs when investors don’t see it clearly.
Women’s Health is Mispriced, Not Unproven
The single biggest mistake generalist investors make is treating women’s health as a specialty bet rather than a healthcare investment. They say they believe in the market. They say women are 51% of the population. And then they underwrite the deal like it’s a charitable side project.
They question the total addressable market more aggressively. They ask for more proof points earlier. They scrutinize the founders’ backgrounds differently. They want validation from male KOLs in adjacent specialties before they trust the data. The minute they hear “women’s health,” half of them assume a DTC period app, not an enterprise platform or a diagnostics company embedded in hospital systems.
If you wouldn’t apply that lens to a cardiology AI platform built by two Stanford guys, don’t apply it to a women’s health company.
This isn’t a niche. It’s half the population. It’s lifespan conditions, chronic disease, oncology, cardiovascular health, autoimmune disorders, and metabolic disease. The market has been chronically misclassified, and misclassification is the opportunity. Mispriced markets are exactly where early investors make their strongest returns.
Not Every Company Here Is a Unicorn, and That’s a Good Thing
I hear this one all the time: “This is such a big unmet need. It has to be huge.”
Needing something and building a venture-scale business are two different things. Some women’s health companies should be $200M outcomes. Some should be strategic tuck-ins. Some will be durable, profitable growth businesses. Not everything needs to be a $5B IPO to justify existence.
When investors walk in assuming every company must be a generational unicorn simply because the problem is morally urgent, they distort strategy. They push founders to over-expand, over-hire, and over-promise. That’s not how you build durable companies. That’s how you build casualties and continuously underfund good companies.
Stage-Appropriate Expectations Matter More
This one drives me crazy, personally from experience.
You can’t have thousands of customers at launch in regulated healthcare. You can’t have enterprise contracts signed before you have FDA clearance. You can’t demonstrate scaled reimbursement pathways before pilots.
Yet I routinely see pre-seed and seed-stage women’s health companies asked to show revenue traction and customer density that would be impressive for a Series B.
Early-stage is for validation, iteration, regulatory groundwork, and building clinical trust. If you don’t have the appetite for that risk profile, don’t invest at that stage. But don’t hold women’s health founders to a bar you wouldn’t apply to other healthtech verticals.
And don’t underwrite these deals like they’re fintech plays. Women’s health is infrastructure healthcare. It touches reimbursement. It intersects with public policy. It may require behavior change or clinical workflow change. Those cycles are not SaaS-fast. If you want PE-style predictability, invest later. But don’t back early innovation and then punish it for being healthcare.
Regulatory Timelines Work Differently Here
Women’s health products often sit in gray zones, especially around reproductive health, diagnostics, digital health, and AI. The FDA has evolved. CMS has evolved. State-level policy has evolved. You can’t copy-paste the regulatory strategy from a generic device playbook.
Investors who haven’t done their homework underestimate timelines and overestimate simplicity. Then they blame the operator when approvals take longer than they expected. Regulatory nuance isn’t incompetence. It’s the terrain.
The Go-to-Market Is Nothing Like Enterprise Software
Last year, I went in for a routine mammogram at one of the best hospitals in New York City. The radiologist saw something they couldn’t visualize clearly. Because of the backlog, my follow-up was scheduled three weeks out.
I run a breast imaging company. I’ve worked in diagnostics for over a decade. I helped create the spot mammography technology they used on me. I know how the machines work. I know what dense breast tissue looks like on a screen. I knew, intellectually, that I was almost certainly fine.
My nervous system didn’t care what I knew. For three weeks I couldn’t focus. I over-analyzed everything. I was racked with worry in a way that I, someone who lives inside this industry, could not rationalize my way out of.
When I finally went back for the spot mammogram, I walked out with a bruise on my left breast that lasted weeks and pain that made it difficult to move for days. The result was dense tissue, exactly what I expected. Everything was fine.
But here’s what I couldn’t stop thinking about: if I reacted that way, what happens to the woman who doesn’t know this space at all? The woman who gets that callback and has no framework for what it means? Does she go back for the follow-up? Does she return the next year knowing it could happen again?
That’s the go-to-market reality investors don’t model. You’re not selling software. You’re asking women to walk into an experience that involves fear, pain, vulnerability, and a healthcare system that has dismissed them before. Women are sophisticated healthcare consumers. They’re also exhausted by being told to advocate for themselves inside systems that weren’t built for them.
You can’t market women’s health like you market a workflow optimization tool. Trust has to be earned differently. Channels look different. Messaging matters more. If you don’t understand that, your CAC assumptions will be fantasy.
The Company Types Are Broader Than You Think
Not every women’s health company is a period app.
Some are enterprise SaaS. Some are medical devices. Some are diagnostics platforms. Some are infrastructure plays embedded in hospital systems. The minute an investor hears “women’s health” and assumes a DTC subscription model, I know we’re going to have a long conversation.
Sometimes the highest-leverage move is enabling existing systems to work better for women, not rebuilding the system from scratch.
The Founder Bias Is Real, and It’s Costing You Deals
This one is uncomfortable, but it’s real.
I’ve watched investors ask women about their family support systems, their childcare plans, their emotional resilience in ways they would never ask a male founder.
I’ve seen first-time female CEOs questioned about their “readiness” in rooms where first-time male CEOs were celebrated as bold.
I’ve seen investors suggest mentorship programs and accelerators as prerequisites, not optional supports, as if the founder needs remedial help before being trusted with capital.
We don’t do this to men. If you back first-time male founders in other sectors without blinking, but hesitate here, ask yourself why.
Everyone Is a First-Time CEO Once
Here’s the reality: I’ve been a non-founder CEO. I’ve taken over companies. I’ve built from scratch. I’ve learned in real time. That’s the job.
If you only fund repeat founders with exits, you are funding a very narrow demographic. And in women’s health, that demographic historically has not been women.
You can’t complain about the lack of exits and then refuse to fund the women building their first one.
The Quiet Contradiction at the Top
I have seen all-male leadership teams running women’s health companies with zero women in senior roles. And no one asks why.
But when a woman leads a women’s health company, suddenly her objectivity is questioned. Is she “too close” to the problem? Is she “too passionate”?
Passion isn’t a liability. It’s pattern recognition plus lived experience.
If you’re not questioning why a women’s health company has no women in leadership, but you are questioning whether a female CEO can be “objective,” that’s a bias problem, not a diligence problem.
The Investors Who Get It Right Do This
Women’s health investing is not philanthropy. It’s not trend-chasing. It’s not a side pocket of your fund to check a box.
It’s a complex, regulated, high-impact, infrastructure-level sector that requires discipline, patience, and conviction. The market fundamentals are strong. The gaps are massive. The consumer demand is unavoidable. And the first companies that build trust, distribution, and clinical credibility will dominate categories that have been stagnant for decades.
The investors who get it right underwrite it like healthcare, not charity. They calibrate expectations to stage and regulatory reality. And they trust the operators they back.
If you can’t do those three things, you’re not early. You’re unprepared.
And women’s health doesn’t need more tourists. It needs real partners.